Indications
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test.
Dosage And Administration
Patient Selection: Select patients for treatment with Capmatinib based on the presence of a mutation that leads to MET exon 14 skipping in tumor or plasma specimens. If a mutation that leads to MET exon 14 skipping is not detected in a plasma specimen, test tumor tissue if feasible.
Recommended Dose: The recommended dosage of Capmatinib is 400 mg orally twice daily with or without food. Swallow Capmatinib tablets whole. Do not break, crush or chew the tablets. If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose at its scheduled time.
Side Effects
Lung or breathing problems
Liver problems.
Pancreas problems.
Swelling of your hands or feet
Nausea
Muscle or bone pain
Tiredness and weakness
Vomiting
Trouble breathing
Cough
Loss of appetite
Changes in certain blood tests
Precautions And Warnings
Interstitial Lung Disease (ILD): Immediately withhold Capmatinib in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified.
Hepatotoxicity: Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of Capmatinib, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Based on the severity of the adverse reaction, withhold, dose reduce, or permanently discontinue Capmatinib.
Pancreatic Toxicity: Monitor amylase and lipase at baseline and regularly during treatment with Capmatinib. Based on the severity of the adverse drug reaction, temporarily withhold, dose reduce, or permanently discontinue Capmatinib.
Risk of Photosensitivity: Advise patients to limit direct ultraviolet exposure during treatment with Capmatinib.
Embryo-Fetal Toxicity: Based on findings from animal studies and its mechanism of action, Capmatinib can cause fetal harm when administered to a pregnant woman.
Pregnancy And Lactation
Pregnancy: Capmatinib can cause fetal harm when administered to a pregnant woman. There are no available data on Capmatinib use in pregnant women. Advise pregnant women of the potential risk to a fetus.
Lactation: Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Capmatinib and for 1 week after the last dose.
Females and Males of Reproductive Potential: Based on animal data, Capmatinib can cause malformations at doses less than the human exposure based on AUC at the 400 mg twice daily clinical dose.
Pregnancy Testing: Verify pregnancy status for females of reproductive potential prior to starting treatment with Capmatinib.
Contraception-
Females: Advise females of reproductive potential to use effective contraception during treatment with Capmatinib and for 1 week after the last dose.
Males: Advise males with female partners of reproductive potential to use effective contraception during treatment with Capmatinib and for 1 week after the last dose